Nevirapine-selected mutations Y181I/C of HIV-1 reverse transcriptase confer cross-resistance to stavudine.
Stavudine administration did not increase the frequency of Y181I/C reverse transcriptase (RT) mutations in non-nucleoside reverse transcriptase inhibitor (NNRTI)-treated patients. However, recombinant Y181C HIV-1 showed reduced stavudine susceptibility with respect to both recombinant wild-type and K103N HIV-1 strains. In addition, recombinant Y181I RT enzyme showed reduced susceptibility to stavudine with respect to both wild-type and K103N RT. A previously unnoticed role of Y181I/C RT changes selected by nevirapine or other NNRTI in determining stavudine resistance is documented.
Baldanti
Fausto
F
Servizio di Virologia, IRCCS Policlinico San Matteo, Pavia, Italy.
Paolucci
Stefania
S
Maga
Giovanni
G
Labo
Nazzarena
N
Hübscher
Ulrich
U
Skoblov
Alexander Yu
AY
Victorova
Lyubov
L
Spadari
Silvio
S
Minoli
Lorenzo
L
Gerna
Giuseppe
G
D023241:Antiretroviral Therapy, Highly Active; D024882:Drug Resistance, Viral / Q000235:genetics*; D054303:HIV Reverse Transcriptase / Q000235:genetics*; D015497:HIV-1 / Q000235:genetics*; D006801:Humans; D009154:Mutation; D019829:Nevirapine / Q000627:therapeutic use*; D011446:Prospective Studies; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use*; D018119:Stavudine / Q000627:therapeutic use*; D017211:Treatment Failure
D018894:Reverse Transcriptase Inhibitors; D019829:Nevirapine; D018119:Stavudine; D054303:HIV Reverse Transcriptase